主要文件

查看所有文档

73529

氯倍他索

Name: 氯倍他索
Brand: SIAL

pharmaceutical impurity standard, ≥95.0% (HPLC)

别名:

Clobetasol propionate impurity G (PhEur), (11β,16β)-21-Chloro-9-fluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₂H₂₈ClFO₄

化学文摘社编号:

25122-41-2

分子量:

410.91

UNSPSC Code:

41116107

PubChem Substance ID:

329763802

EC Number:

246-633-8

MDL number:

MFCD03695616

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

analytical standard

assay

≥95.0% (HPLC)

shelf life

limited shelf life, expiry date on the label

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

impurities

≤10.0% related substances, ≤5.0% solvents, ≤5.0% water

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl

InChI

1S/C22H28ClFO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1

InChI key

FCSHDIVRCWTZOX-DVTGEIKXSA-N

说明

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

pictograms

GHS08

signalword

Danger

hcodes

H360Df,H373,H413

pcodes

P201 - P273 - P308 + P313

Hazard Classifications

Aquatic Chronic 4 - Repr. 1B - STOT RE 2

target_organs

Adrenal gland,Immune system

存储类别

6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

BCBS7533V

BCBR2508V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Non-invasive clinical and microscopic evaluation of the response to treatment with clobetasol cream vs. calcipotriol/betamethasone dipropionate foam in mild to moderate plaque psoriasis: an investigator-initiated, phase IV, unicentric, open, randomized clinical trial.

O Yélamos et al.

Journal of the European Academy of Dermatology and Venereology : JEADV, 35(1), 143-149 (2020-05-05)

Treatment response for psoriasis is typically evaluated using clinical scores. However, patients can relapse after clinical clearance, suggesting persistent inflammation. Dermoscopy, reflectance confocal microscopy (RCM) and optical coherence tomography (OCT) can non-invasively improve treatment response assessment. To compare the clinical

Topical clobetasol-17-propionate: review of its clinical efficacy and safety.

E A Olsen et al.

Journal of the American Academy of Dermatology, 15(2 Pt 1), 246-255 (1986-08-01)

Clobetasol-17-propionate, the most potent of currently available topical steroids as predicted by the vasoconstrictor assay, has just been approved in the United States. In psoriasis, it has proved significantly more effective than class II steroids and as or more effective

Undeclared formaldehyde levels in patient consumer products: formaldehyde test kit utility.

Jason E Ham et al.

Cutaneous and ocular toxicology, 38(2), 112-117 (2018-05-04)

Formaldehyde allergic contact dermatitis (ACD) may be due to products with free formaldehyde or formaldehyde-releasing agents; however, assessment of formaldehyde levels in such products is infrequently conducted. The present study quantifies total releasable formaldehyde from "in-use" products associated with formaldehyde

查看所有相关文献